Hikma Pharmaceuticals USA Inc.
US H-1B Labor Condition Application activity for Hikma Pharmaceuticals USA Inc.. Filed 106 disclosures between FY2018 and FY2026 from worksites with a NJ headquarters indicator.
H-1B outcome breakdown
Share of Hikma Pharmaceuticals USA Inc.’s LCAs by DOL case status, all fiscal years. Use the year filter above for a single-year breakdown.
| Outcome | Share |
|---|---|
| Certified | 79.3% |
| Cert-withdrawn | 17.9% |
| Withdrawn | 1.9% |
| Denied | 0.9% |
Top occupations sponsored
SOC codes filed most by Hikma Pharmaceuticals USA Inc. across all fiscal years. Click any row to open the national salary guide.
| # | SOC | Title | Filings |
|---|---|---|---|
| 1 | 19-2031 | Chemists | 28 |
| 2 | 17-2112 | Industrial Engineers | 17 |
| 3 | 15-1252 | Software Developers | 7 |
| 4 | 11-9121 | Natural Sciences Managers | 4 |
| 5 | 15-2051 | Data Scientists | 3 |
| 6 | 13-1041 | Compliance Officers | 3 |
| 7 | 19-1042 | Medical Scientists, Except Epidemiologists | 3 |
| 8 | 17-2072 | Electronics Engineers, Except Computer | 2 |
| 9 | 13-2051 | Financial and Investment Analysts | 2 |
| 10 | 11-9199 | Managers, All Other | 2 |
H-1B filings by fiscal year
Year-over-year H-1B filing volume — a hiring-demand signal, not headcount.
| Year | Filings |
|---|---|
| FY2018 | 6 |
| FY2019 | 8 |
| FY2020 | 4 |
| FY2021 | 15 |
| FY2022 | 1 |
| FY2023 | 16 |
| FY2024 | 24 |
| FY2025 | 16 |
| FY2026 | 16 |
| Period | Value |
|---|---|
| FY2018 | 6 |
| FY2019 | 8 |
| FY2020 | 4 |
| FY2021 | 15 |
| FY2022 | 1 |
| FY2023 | 16 |
| FY2024 | 24 |
| FY2025 | 16 |
| FY2026 | 16 |
This employer filed at least one WARN Act notice in the last 24 months — a state-mandated advance announcement of a planned mass layoff or closure. A notice is an announcement, not a completed layoff, and it is not evidence of any link between the employer’s H-1B filings and its workforce plans.